Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter

WATERTOWN, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader. The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera’s partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. Dosing of the first patient in the AD trial will also generate a milestone payment to Kymera.

“The initiation of dosing in the first Phase 2 trial of KT-474 in HS is an important step in the development of this molecule and a significant achievement for Kymera in demonstrating the potential of protein degradation to transform the treatment of complex, inflammatory diseases with small molecules,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “Based on the encouraging KT-474 Phase 1 results, we believe that this molecule has the potential to offer HS patients a well-tolerated and effective oral drug. We look forward to sharing additional updates as our partner Sanofi advances this program, including dosing the first patient in the second Phase 2 trial in AD later this quarter.”

“At Sanofi, we’ve very excited about the potential of protein degraders to deliver new treatments for immunological and inflammatory diseases by selectively targeting specific proteins and critical pathways, like IRAK4,” said Naimish Patel, MD, Head of Global Development, Immunology and Inflammation, Sanofi. “HS is a chronic, debilitating skin disease whereby there remains a tremendous need for new treatment options. We look forward to progressing the Phase 2 program in HS and AD.”